Therefore, PD-1/PD-L1 pathway targeted immunotherapy has become a standard option for the management of locally advanced and metastatic lung cancer.5,6,8,9 In clinical trials, anti–PD-1 and anti–PD-L1 antibodies produced a durable response in approximately 20% of unselected patients with advanced NSCLC in the second or third lines of treatment.8,9 There is no optimal predictive biomarker to select patients that would likely respond to anti-PD-1/PD-L1 therapies. Here, CD274 is linked to non-small cell lung carcinoma.